nodes	percent_of_prediction	percent_of_DWPC	metapath
Lapatinib—ERBB2—prostate cancer	0.166	0.432	CbGaD
Lapatinib—EGFR—prostate cancer	0.0785	0.204	CbGaD
Lapatinib—CYP3A5—prostate cancer	0.0663	0.172	CbGaD
Lapatinib—CYP2C19—prostate cancer	0.0451	0.117	CbGaD
Lapatinib—EGFR—Docetaxel—prostate cancer	0.0425	0.126	CbGbCtD
Lapatinib—CYP3A4—prostate cancer	0.0287	0.0746	CbGaD
Lapatinib—CYP2C8—Nilutamide—prostate cancer	0.0182	0.0538	CbGbCtD
Lapatinib—CYP3A5—Flutamide—prostate cancer	0.0157	0.0463	CbGbCtD
Lapatinib—CYP2C19—Bicalutamide—prostate cancer	0.0153	0.0451	CbGbCtD
Lapatinib—CYP2C19—Nilutamide—prostate cancer	0.0153	0.0451	CbGbCtD
Lapatinib—CYP2C8—Abiraterone—prostate cancer	0.0151	0.0446	CbGbCtD
Lapatinib—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.014	0.0415	CbGbCtD
Lapatinib—CYP2C19—Flutamide—prostate cancer	0.0126	0.0374	CbGbCtD
Lapatinib—CYP3A5—Cabazitaxel—prostate cancer	0.0116	0.0343	CbGbCtD
Lapatinib—ABCB1—Estramustine—prostate cancer	0.0115	0.0338	CbGbCtD
Lapatinib—CYP3A5—Estrone—prostate cancer	0.0113	0.0335	CbGbCtD
Lapatinib—CYP2C8—Cabazitaxel—prostate cancer	0.0112	0.033	CbGbCtD
Lapatinib—CYP2C8—Ethinyl Estradiol—prostate cancer	0.00972	0.0287	CbGbCtD
Lapatinib—ABCB1—Cabazitaxel—prostate cancer	0.00755	0.0223	CbGbCtD
Lapatinib—CYP3A4—Bicalutamide—prostate cancer	0.00738	0.0218	CbGbCtD
Lapatinib—ABCB1—Estrone—prostate cancer	0.00738	0.0218	CbGbCtD
Lapatinib—CYP3A4—Estramustine—prostate cancer	0.00686	0.0203	CbGbCtD
Lapatinib—ABCB1—Ethinyl Estradiol—prostate cancer	0.00658	0.0194	CbGbCtD
Lapatinib—CYP3A5—Estradiol—prostate cancer	0.00651	0.0192	CbGbCtD
Lapatinib—CYP2C8—Estradiol—prostate cancer	0.00626	0.0185	CbGbCtD
Lapatinib—CYP3A4—Abiraterone—prostate cancer	0.00611	0.0181	CbGbCtD
Lapatinib—CYP3A4—Flutamide—prostate cancer	0.00611	0.0181	CbGbCtD
Lapatinib—CYP2C19—Estradiol—prostate cancer	0.00525	0.0155	CbGbCtD
Lapatinib—ABCB1—Conjugated Estrogens—prostate cancer	0.00483	0.0143	CbGbCtD
Lapatinib—CYP3A4—Cabazitaxel—prostate cancer	0.00452	0.0134	CbGbCtD
Lapatinib—CYP2C19—Prednisone—prostate cancer	0.00452	0.0133	CbGbCtD
Lapatinib—CYP3A4—Estrone—prostate cancer	0.00442	0.0131	CbGbCtD
Lapatinib—ABCB1—Mitoxantrone—prostate cancer	0.00439	0.013	CbGbCtD
Lapatinib—CYP3A5—Etoposide—prostate cancer	0.00425	0.0126	CbGbCtD
Lapatinib—ABCB1—Estradiol—prostate cancer	0.00424	0.0125	CbGbCtD
Lapatinib—CYP2C8—Etoposide—prostate cancer	0.00409	0.0121	CbGbCtD
Lapatinib—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00394	0.0116	CbGbCtD
Lapatinib—CYP3A5—Docetaxel—prostate cancer	0.00389	0.0115	CbGbCtD
Lapatinib—ABCB1—Prednisone—prostate cancer	0.00364	0.0108	CbGbCtD
Lapatinib—CYP3A4—Conjugated Estrogens—prostate cancer	0.00289	0.00855	CbGbCtD
Lapatinib—ABCB1—Etoposide—prostate cancer	0.00277	0.00818	CbGbCtD
Lapatinib—CYP3A4—Mitoxantrone—prostate cancer	0.00263	0.00777	CbGbCtD
Lapatinib—TAP1—prostate gland—prostate cancer	0.00256	0.0571	CbGeAlD
Lapatinib—CYP3A4—Estradiol—prostate cancer	0.00254	0.0075	CbGbCtD
Lapatinib—ABCB1—Docetaxel—prostate cancer	0.00253	0.00748	CbGbCtD
Lapatinib—PIK3C2B—prostate gland—prostate cancer	0.0024	0.0536	CbGeAlD
Lapatinib—CYP3A4—Prednisone—prostate cancer	0.00218	0.00645	CbGbCtD
Lapatinib—TAP1—seminal vesicle—prostate cancer	0.00216	0.0483	CbGeAlD
Lapatinib—PIK3C2B—seminal vesicle—prostate cancer	0.00203	0.0453	CbGeAlD
Lapatinib—ABCB1—Doxorubicin—prostate cancer	0.00189	0.00558	CbGbCtD
Lapatinib—ERBB2—prostate gland—prostate cancer	0.00187	0.0417	CbGeAlD
Lapatinib—ERBB4—prostate gland—prostate cancer	0.00187	0.0417	CbGeAlD
Lapatinib—PI4KB—prostate gland—prostate cancer	0.00175	0.039	CbGeAlD
Lapatinib—TAP1—urethra—prostate cancer	0.00171	0.0382	CbGeAlD
Lapatinib—CYP3A4—Etoposide—prostate cancer	0.00166	0.0049	CbGbCtD
Lapatinib—CYP2C19—urine—prostate cancer	0.00162	0.0361	CbGeAlD
Lapatinib—PIK3C2B—urethra—prostate cancer	0.00161	0.0359	CbGeAlD
Lapatinib—EGFR—prostate gland—prostate cancer	0.00158	0.0353	CbGeAlD
Lapatinib—CYP3A4—Docetaxel—prostate cancer	0.00152	0.00448	CbGbCtD
Lapatinib—PI4KB—seminal vesicle—prostate cancer	0.00148	0.033	CbGeAlD
Lapatinib—ERBB2—epithelium—prostate cancer	0.00137	0.0306	CbGeAlD
Lapatinib—ERBB4—epithelium—prostate cancer	0.00137	0.0306	CbGeAlD
Lapatinib—TAP1—bone marrow—prostate cancer	0.00132	0.0294	CbGeAlD
Lapatinib—ERBB2—renal system—prostate cancer	0.00127	0.0284	CbGeAlD
Lapatinib—PIK3C2B—bone marrow—prostate cancer	0.00124	0.0276	CbGeAlD
Lapatinib—Gefitinib—IRAK4—prostate cancer	0.00123	0.375	CrCbGaD
Lapatinib—PI4KB—renal system—prostate cancer	0.00119	0.0266	CbGeAlD
Lapatinib—PI4KB—urethra—prostate cancer	0.00117	0.0261	CbGeAlD
Lapatinib—CYP3A4—Doxorubicin—prostate cancer	0.00113	0.00334	CbGbCtD
Lapatinib—TAP1—testis—prostate cancer	0.00113	0.0251	CbGeAlD
Lapatinib—PIK3C2B—testis—prostate cancer	0.00106	0.0236	CbGeAlD
Lapatinib—CYP3A4—urine—prostate cancer	0.000958	0.0214	CbGeAlD
Lapatinib—PI4KB—bone marrow—prostate cancer	0.000902	0.0201	CbGeAlD
Lapatinib—ERBB2—testis—prostate cancer	0.000823	0.0184	CbGeAlD
Lapatinib—ERBB4—testis—prostate cancer	0.000823	0.0184	CbGeAlD
Lapatinib—TAP1—lymph node—prostate cancer	0.000817	0.0182	CbGeAlD
Lapatinib—PI4KB—testis—prostate cancer	0.000771	0.0172	CbGeAlD
Lapatinib—PIK3C2B—lymph node—prostate cancer	0.000767	0.0171	CbGeAlD
Lapatinib—EGFR—testis—prostate cancer	0.000698	0.0156	CbGeAlD
Lapatinib—Gefitinib—CHEK2—prostate cancer	0.000633	0.193	CrCbGaD
Lapatinib—ERBB2—lymph node—prostate cancer	0.000597	0.0133	CbGeAlD
Lapatinib—Gefitinib—ERBB3—prostate cancer	0.000564	0.172	CrCbGaD
Lapatinib—PI4KB—lymph node—prostate cancer	0.000559	0.0125	CbGeAlD
Lapatinib—EGFR—lymph node—prostate cancer	0.000506	0.0113	CbGeAlD
Lapatinib—CYP3A5—prostate gland—prostate cancer	0.000458	0.0102	CbGeAlD
Lapatinib—CYP2C8—renal system—prostate cancer	0.000346	0.00772	CbGeAlD
Lapatinib—PIK3C2B—Exemestane—Estrone—prostate cancer	0.000315	0.114	CbGdCrCtD
Lapatinib—CYP3A5—renal system—prostate cancer	0.000312	0.00697	CbGeAlD
Lapatinib—PIK3C2B—Exemestane—Conjugated Estrogens—prostate cancer	0.000277	0.101	CbGdCrCtD
Lapatinib—ERBB2—Exemestane—Estrone—prostate cancer	0.000259	0.094	CbGdCrCtD
Lapatinib—Gefitinib—EGFR—prostate cancer	0.000253	0.0772	CrCbGaD
Lapatinib—ABCB1—prostate gland—prostate cancer	0.000243	0.00543	CbGeAlD
Lapatinib—PIK3C2B—Testosterone Propionate—Estradiol valerate/Dienogest—prostate cancer	0.000236	0.0858	CbGdCrCtD
Lapatinib—CYP3A4—renal system—prostate cancer	0.000234	0.00523	CbGeAlD
Lapatinib—ERBB2—Exemestane—Conjugated Estrogens—prostate cancer	0.000228	0.0828	CbGdCrCtD
Lapatinib—CYP2C8—testis—prostate cancer	0.000224	0.00499	CbGeAlD
Lapatinib—Gefitinib—CYP3A5—prostate cancer	0.000213	0.0652	CrCbGaD
Lapatinib—ABCB1—seminal vesicle—prostate cancer	0.000206	0.00459	CbGeAlD
Lapatinib—PIK3C2B—Podofilox—Etoposide—prostate cancer	0.000198	0.0719	CbGdCrCtD
Lapatinib—PIK3C2B—Levorphanol—Estrone—prostate cancer	0.000196	0.0712	CbGdCrCtD
Lapatinib—ABCB1—epithelium—prostate cancer	0.000179	0.00399	CbGeAlD
Lapatinib—ABCB1—renal system—prostate cancer	0.000166	0.0037	CbGeAlD
Lapatinib—ERBB2—Podofilox—Etoposide—prostate cancer	0.000163	0.0592	CbGdCrCtD
Lapatinib—ABCB1—urethra—prostate cancer	0.000163	0.00363	CbGeAlD
Lapatinib—PIK3C2B—Levorphanol—Estradiol—prostate cancer	0.000149	0.054	CbGdCrCtD
Lapatinib—Gefitinib—CYP2C19—prostate cancer	0.000145	0.0444	CrCbGaD
Lapatinib—Gefitinib—CYP1A1—prostate cancer	0.000145	0.0442	CrCbGaD
Lapatinib—ABCB1—bone marrow—prostate cancer	0.000125	0.0028	CbGeAlD
Lapatinib—ABCB1—testis—prostate cancer	0.000107	0.00239	CbGeAlD
Lapatinib—PIK3C2B—Danazol—Ethinyl Estradiol—prostate cancer	9.82e-05	0.0356	CbGdCrCtD
Lapatinib—Gefitinib—CYP3A4—prostate cancer	9.24e-05	0.0282	CrCbGaD
Lapatinib—PIK3C2B—Norethindrone—Ethinyl Estradiol—prostate cancer	8.85e-05	0.0321	CbGdCrCtD
Lapatinib—ERBB2—Doxorubicin—Epirubicin—prostate cancer	8.51e-05	0.0309	CbGdCrCtD
Lapatinib—PIK3C2B—Exemestane—Prednisone—prostate cancer	8.18e-05	0.0297	CbGdCrCtD
Lapatinib—ERBB2—Epirubicin—Doxorubicin—prostate cancer	7.87e-05	0.0286	CbGdCrCtD
Lapatinib—ABCB1—lymph node—prostate cancer	7.78e-05	0.00173	CbGeAlD
Lapatinib—PIK3C2B—Levonorgestrel—Ethinyl Estradiol—prostate cancer	7.04e-05	0.0256	CbGdCrCtD
Lapatinib—ERBB2—Exemestane—Prednisone—prostate cancer	6.74e-05	0.0244	CbGdCrCtD
Lapatinib—ERBB2—Levonorgestrel—Ethinyl Estradiol—prostate cancer	5.8e-05	0.021	CbGdCrCtD
Lapatinib—Dermatitis—Goserelin—prostate cancer	5.73e-05	0.000516	CcSEcCtD
Lapatinib—Vomiting—Conjugated Estrogens—prostate cancer	5.72e-05	0.000516	CcSEcCtD
Lapatinib—Mental disorder—Docetaxel—prostate cancer	5.72e-05	0.000516	CcSEcCtD
Lapatinib—Immune system disorder—Capecitabine—prostate cancer	5.71e-05	0.000515	CcSEcCtD
Lapatinib—Mediastinal disorder—Capecitabine—prostate cancer	5.7e-05	0.000514	CcSEcCtD
Lapatinib—Abdominal pain—Estradiol—prostate cancer	5.7e-05	0.000513	CcSEcCtD
Lapatinib—Headache—Goserelin—prostate cancer	5.69e-05	0.000513	CcSEcCtD
Lapatinib—Malnutrition—Docetaxel—prostate cancer	5.69e-05	0.000513	CcSEcCtD
Lapatinib—Rash—Conjugated Estrogens—prostate cancer	5.68e-05	0.000512	CcSEcCtD
Lapatinib—Dermatitis—Conjugated Estrogens—prostate cancer	5.67e-05	0.000511	CcSEcCtD
Lapatinib—Headache—Conjugated Estrogens—prostate cancer	5.64e-05	0.000508	CcSEcCtD
Lapatinib—Alanine aminotransferase increased—Epirubicin—prostate cancer	5.62e-05	0.000506	CcSEcCtD
Lapatinib—Alopecia—Capecitabine—prostate cancer	5.59e-05	0.000504	CcSEcCtD
Lapatinib—Anaphylactic shock—Etoposide—prostate cancer	5.58e-05	0.000503	CcSEcCtD
Lapatinib—Infection—Etoposide—prostate cancer	5.55e-05	0.0005	CcSEcCtD
Lapatinib—Mental disorder—Capecitabine—prostate cancer	5.54e-05	0.0005	CcSEcCtD
Lapatinib—Connective tissue disorder—Prednisone—prostate cancer	5.54e-05	0.000499	CcSEcCtD
Lapatinib—Malnutrition—Capecitabine—prostate cancer	5.51e-05	0.000496	CcSEcCtD
Lapatinib—Back pain—Docetaxel—prostate cancer	5.5e-05	0.000496	CcSEcCtD
Lapatinib—Gastrointestinal pain—Mitoxantrone—prostate cancer	5.49e-05	0.000495	CcSEcCtD
Lapatinib—Dehydration—Doxorubicin—prostate cancer	5.48e-05	0.000494	CcSEcCtD
Lapatinib—Skin disorder—Etoposide—prostate cancer	5.42e-05	0.000489	CcSEcCtD
Lapatinib—Dry skin—Doxorubicin—prostate cancer	5.4e-05	0.000487	CcSEcCtD
Lapatinib—Nausea—Goserelin—prostate cancer	5.4e-05	0.000487	CcSEcCtD
Lapatinib—Nausea—Conjugated Estrogens—prostate cancer	5.35e-05	0.000482	CcSEcCtD
Lapatinib—Back pain—Capecitabine—prostate cancer	5.33e-05	0.00048	CcSEcCtD
Lapatinib—Anorexia—Etoposide—prostate cancer	5.32e-05	0.00048	CcSEcCtD
Lapatinib—Hypersensitivity—Estradiol—prostate cancer	5.31e-05	0.000479	CcSEcCtD
Lapatinib—Abdominal pain—Mitoxantrone—prostate cancer	5.31e-05	0.000478	CcSEcCtD
Lapatinib—Anaemia—Docetaxel—prostate cancer	5.26e-05	0.000474	CcSEcCtD
Lapatinib—Alanine aminotransferase increased—Doxorubicin—prostate cancer	5.2e-05	0.000469	CcSEcCtD
Lapatinib—Asthenia—Estradiol—prostate cancer	5.17e-05	0.000466	CcSEcCtD
Lapatinib—Neutropenia—Epirubicin—prostate cancer	5.15e-05	0.000464	CcSEcCtD
Lapatinib—Angiopathy—Prednisone—prostate cancer	5.11e-05	0.000461	CcSEcCtD
Lapatinib—Pruritus—Estradiol—prostate cancer	5.1e-05	0.00046	CcSEcCtD
Lapatinib—Leukopenia—Docetaxel—prostate cancer	5.09e-05	0.000459	CcSEcCtD
Lapatinib—Anaemia—Capecitabine—prostate cancer	5.09e-05	0.000459	CcSEcCtD
Lapatinib—Immune system disorder—Prednisone—prostate cancer	5.09e-05	0.000459	CcSEcCtD
Lapatinib—Palpitations—Docetaxel—prostate cancer	5.03e-05	0.000453	CcSEcCtD
Lapatinib—Dyspnoea—Etoposide—prostate cancer	4.98e-05	0.000449	CcSEcCtD
Lapatinib—Alopecia—Prednisone—prostate cancer	4.98e-05	0.000449	CcSEcCtD
Lapatinib—Cough—Docetaxel—prostate cancer	4.96e-05	0.000447	CcSEcCtD
Lapatinib—Hypersensitivity—Mitoxantrone—prostate cancer	4.95e-05	0.000446	CcSEcCtD
Lapatinib—Pneumonia—Epirubicin—prostate cancer	4.94e-05	0.000445	CcSEcCtD
Lapatinib—Mental disorder—Prednisone—prostate cancer	4.94e-05	0.000445	CcSEcCtD
Lapatinib—Diarrhoea—Estradiol—prostate cancer	4.93e-05	0.000444	CcSEcCtD
Lapatinib—Leukopenia—Capecitabine—prostate cancer	4.93e-05	0.000444	CcSEcCtD
Lapatinib—Infestation NOS—Epirubicin—prostate cancer	4.91e-05	0.000442	CcSEcCtD
Lapatinib—Infestation—Epirubicin—prostate cancer	4.91e-05	0.000442	CcSEcCtD
Lapatinib—Malnutrition—Prednisone—prostate cancer	4.9e-05	0.000442	CcSEcCtD
Lapatinib—Palpitations—Capecitabine—prostate cancer	4.87e-05	0.000439	CcSEcCtD
Lapatinib—Decreased appetite—Etoposide—prostate cancer	4.85e-05	0.000438	CcSEcCtD
Lapatinib—Arthralgia—Docetaxel—prostate cancer	4.84e-05	0.000436	CcSEcCtD
Lapatinib—Myalgia—Docetaxel—prostate cancer	4.84e-05	0.000436	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Etoposide—prostate cancer	4.82e-05	0.000435	CcSEcCtD
Lapatinib—Asthenia—Mitoxantrone—prostate cancer	4.82e-05	0.000434	CcSEcCtD
Lapatinib—Fatigue—Etoposide—prostate cancer	4.82e-05	0.000434	CcSEcCtD
Lapatinib—Neuropathy peripheral—Epirubicin—prostate cancer	4.81e-05	0.000434	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	4.81e-05	0.000433	CcSEcCtD
Lapatinib—Cough—Capecitabine—prostate cancer	4.8e-05	0.000433	CcSEcCtD
Lapatinib—Stomatitis—Epirubicin—prostate cancer	4.78e-05	0.000431	CcSEcCtD
Lapatinib—Constipation—Etoposide—prostate cancer	4.78e-05	0.000431	CcSEcCtD
Lapatinib—Neutropenia—Doxorubicin—prostate cancer	4.76e-05	0.000429	CcSEcCtD
Lapatinib—Myalgia—Capecitabine—prostate cancer	4.69e-05	0.000423	CcSEcCtD
Lapatinib—Arthralgia—Capecitabine—prostate cancer	4.69e-05	0.000423	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	4.66e-05	0.00042	CcSEcCtD
Lapatinib—Hepatobiliary disease—Epirubicin—prostate cancer	4.64e-05	0.000418	CcSEcCtD
Lapatinib—Anaphylactic shock—Docetaxel—prostate cancer	4.64e-05	0.000418	CcSEcCtD
Lapatinib—Epistaxis—Epirubicin—prostate cancer	4.63e-05	0.000417	CcSEcCtD
Lapatinib—Infection—Docetaxel—prostate cancer	4.61e-05	0.000416	CcSEcCtD
Lapatinib—Diarrhoea—Mitoxantrone—prostate cancer	4.59e-05	0.000414	CcSEcCtD
Lapatinib—Vomiting—Estradiol—prostate cancer	4.58e-05	0.000413	CcSEcCtD
Lapatinib—Pneumonia—Doxorubicin—prostate cancer	4.57e-05	0.000412	CcSEcCtD
Lapatinib—Gastrointestinal pain—Etoposide—prostate cancer	4.57e-05	0.000412	CcSEcCtD
Lapatinib—Nervous system disorder—Docetaxel—prostate cancer	4.55e-05	0.00041	CcSEcCtD
Lapatinib—Rash—Estradiol—prostate cancer	4.54e-05	0.00041	CcSEcCtD
Lapatinib—Infestation—Doxorubicin—prostate cancer	4.54e-05	0.000409	CcSEcCtD
Lapatinib—Infestation NOS—Doxorubicin—prostate cancer	4.54e-05	0.000409	CcSEcCtD
Lapatinib—Dermatitis—Estradiol—prostate cancer	4.54e-05	0.000409	CcSEcCtD
Lapatinib—Anaemia—Prednisone—prostate cancer	4.53e-05	0.000409	CcSEcCtD
Lapatinib—Headache—Estradiol—prostate cancer	4.51e-05	0.000407	CcSEcCtD
Lapatinib—Skin disorder—Docetaxel—prostate cancer	4.51e-05	0.000406	CcSEcCtD
Lapatinib—Infection—Capecitabine—prostate cancer	4.46e-05	0.000402	CcSEcCtD
Lapatinib—Neuropathy peripheral—Doxorubicin—prostate cancer	4.45e-05	0.000401	CcSEcCtD
Lapatinib—Stomatitis—Doxorubicin—prostate cancer	4.43e-05	0.000399	CcSEcCtD
Lapatinib—Anorexia—Docetaxel—prostate cancer	4.42e-05	0.000399	CcSEcCtD
Lapatinib—Abdominal pain—Etoposide—prostate cancer	4.41e-05	0.000398	CcSEcCtD
Lapatinib—Nervous system disorder—Capecitabine—prostate cancer	4.41e-05	0.000397	CcSEcCtD
Lapatinib—Skin disorder—Capecitabine—prostate cancer	4.36e-05	0.000393	CcSEcCtD
Lapatinib—Connective tissue disorder—Epirubicin—prostate cancer	4.33e-05	0.00039	CcSEcCtD
Lapatinib—Hepatobiliary disease—Doxorubicin—prostate cancer	4.3e-05	0.000387	CcSEcCtD
Lapatinib—Epistaxis—Doxorubicin—prostate cancer	4.28e-05	0.000386	CcSEcCtD
Lapatinib—Anorexia—Capecitabine—prostate cancer	4.28e-05	0.000386	CcSEcCtD
Lapatinib—Nausea—Estradiol—prostate cancer	4.28e-05	0.000386	CcSEcCtD
Lapatinib—Vomiting—Mitoxantrone—prostate cancer	4.27e-05	0.000385	CcSEcCtD
Lapatinib—Rash—Mitoxantrone—prostate cancer	4.23e-05	0.000382	CcSEcCtD
Lapatinib—Dermatitis—Mitoxantrone—prostate cancer	4.23e-05	0.000381	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Docetaxel—prostate cancer	4.23e-05	0.000381	CcSEcCtD
Lapatinib—Headache—Mitoxantrone—prostate cancer	4.21e-05	0.000379	CcSEcCtD
Lapatinib—Insomnia—Docetaxel—prostate cancer	4.2e-05	0.000378	CcSEcCtD
Lapatinib—Arthralgia—Prednisone—prostate cancer	4.18e-05	0.000376	CcSEcCtD
Lapatinib—Myalgia—Prednisone—prostate cancer	4.18e-05	0.000376	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	4.15e-05	0.000374	CcSEcCtD
Lapatinib—Dyspnoea—Docetaxel—prostate cancer	4.14e-05	0.000373	CcSEcCtD
Lapatinib—Hypersensitivity—Etoposide—prostate cancer	4.11e-05	0.000371	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Capecitabine—prostate cancer	4.09e-05	0.000369	CcSEcCtD
Lapatinib—Cardiac disorder—Epirubicin—prostate cancer	4.09e-05	0.000369	CcSEcCtD
Lapatinib—Dyspepsia—Docetaxel—prostate cancer	4.09e-05	0.000368	CcSEcCtD
Lapatinib—Insomnia—Capecitabine—prostate cancer	4.06e-05	0.000366	CcSEcCtD
Lapatinib—Decreased appetite—Docetaxel—prostate cancer	4.03e-05	0.000364	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Docetaxel—prostate cancer	4.01e-05	0.000361	CcSEcCtD
Lapatinib—Asthenia—Etoposide—prostate cancer	4.01e-05	0.000361	CcSEcCtD
Lapatinib—Connective tissue disorder—Doxorubicin—prostate cancer	4.01e-05	0.000361	CcSEcCtD
Lapatinib—Dyspnoea—Capecitabine—prostate cancer	4.01e-05	0.000361	CcSEcCtD
Lapatinib—Anaphylactic shock—Prednisone—prostate cancer	4e-05	0.000361	CcSEcCtD
Lapatinib—Fatigue—Docetaxel—prostate cancer	4e-05	0.000361	CcSEcCtD
Lapatinib—Angiopathy—Epirubicin—prostate cancer	4e-05	0.00036	CcSEcCtD
Lapatinib—Nausea—Mitoxantrone—prostate cancer	3.99e-05	0.000359	CcSEcCtD
Lapatinib—Immune system disorder—Epirubicin—prostate cancer	3.98e-05	0.000359	CcSEcCtD
Lapatinib—Infection—Prednisone—prostate cancer	3.98e-05	0.000358	CcSEcCtD
Lapatinib—Mediastinal disorder—Epirubicin—prostate cancer	3.97e-05	0.000358	CcSEcCtD
Lapatinib—Constipation—Docetaxel—prostate cancer	3.97e-05	0.000358	CcSEcCtD
Lapatinib—Dyspepsia—Capecitabine—prostate cancer	3.96e-05	0.000357	CcSEcCtD
Lapatinib—Pruritus—Etoposide—prostate cancer	3.95e-05	0.000356	CcSEcCtD
Lapatinib—Nervous system disorder—Prednisone—prostate cancer	3.93e-05	0.000354	CcSEcCtD
Lapatinib—Decreased appetite—Capecitabine—prostate cancer	3.91e-05	0.000352	CcSEcCtD
Lapatinib—Alopecia—Epirubicin—prostate cancer	3.89e-05	0.000351	CcSEcCtD
Lapatinib—Skin disorder—Prednisone—prostate cancer	3.89e-05	0.00035	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Capecitabine—prostate cancer	3.88e-05	0.00035	CcSEcCtD
Lapatinib—Fatigue—Capecitabine—prostate cancer	3.87e-05	0.000349	CcSEcCtD
Lapatinib—Mental disorder—Epirubicin—prostate cancer	3.86e-05	0.000348	CcSEcCtD
Lapatinib—Constipation—Capecitabine—prostate cancer	3.84e-05	0.000346	CcSEcCtD
Lapatinib—Malnutrition—Epirubicin—prostate cancer	3.84e-05	0.000346	CcSEcCtD
Lapatinib—Diarrhoea—Etoposide—prostate cancer	3.82e-05	0.000344	CcSEcCtD
Lapatinib—Anorexia—Prednisone—prostate cancer	3.82e-05	0.000344	CcSEcCtD
Lapatinib—Gastrointestinal pain—Docetaxel—prostate cancer	3.8e-05	0.000342	CcSEcCtD
Lapatinib—Cardiac disorder—Doxorubicin—prostate cancer	3.78e-05	0.000341	CcSEcCtD
Lapatinib—Back pain—Epirubicin—prostate cancer	3.71e-05	0.000334	CcSEcCtD
Lapatinib—Angiopathy—Doxorubicin—prostate cancer	3.7e-05	0.000333	CcSEcCtD
Lapatinib—Immune system disorder—Doxorubicin—prostate cancer	3.68e-05	0.000332	CcSEcCtD
Lapatinib—Gastrointestinal pain—Capecitabine—prostate cancer	3.67e-05	0.000331	CcSEcCtD
Lapatinib—Mediastinal disorder—Doxorubicin—prostate cancer	3.67e-05	0.000331	CcSEcCtD
Lapatinib—ERBB2—Triamcinolone—Prednisone—prostate cancer	3.67e-05	0.0133	CbGdCrCtD
Lapatinib—Abdominal pain—Docetaxel—prostate cancer	3.67e-05	0.000331	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Prednisone—prostate cancer	3.65e-05	0.000329	CcSEcCtD
Lapatinib—Insomnia—Prednisone—prostate cancer	3.62e-05	0.000326	CcSEcCtD
Lapatinib—Alopecia—Doxorubicin—prostate cancer	3.6e-05	0.000325	CcSEcCtD
Lapatinib—Mental disorder—Doxorubicin—prostate cancer	3.57e-05	0.000322	CcSEcCtD
Lapatinib—Abdominal pain—Capecitabine—prostate cancer	3.55e-05	0.00032	CcSEcCtD
Lapatinib—Vomiting—Etoposide—prostate cancer	3.55e-05	0.00032	CcSEcCtD
Lapatinib—Malnutrition—Doxorubicin—prostate cancer	3.55e-05	0.00032	CcSEcCtD
Lapatinib—Anaemia—Epirubicin—prostate cancer	3.55e-05	0.00032	CcSEcCtD
Lapatinib—Dyspepsia—Prednisone—prostate cancer	3.52e-05	0.000318	CcSEcCtD
Lapatinib—Rash—Etoposide—prostate cancer	3.52e-05	0.000317	CcSEcCtD
Lapatinib—Dermatitis—Etoposide—prostate cancer	3.52e-05	0.000317	CcSEcCtD
Lapatinib—Headache—Etoposide—prostate cancer	3.5e-05	0.000315	CcSEcCtD
Lapatinib—ERBB2—Desoximetasone—Prednisone—prostate cancer	3.48e-05	0.0126	CbGdCrCtD
Lapatinib—Decreased appetite—Prednisone—prostate cancer	3.48e-05	0.000314	CcSEcCtD
Lapatinib—Fatigue—Prednisone—prostate cancer	3.45e-05	0.000311	CcSEcCtD
Lapatinib—PIK3C2B—Danazol—Prednisone—prostate cancer	3.45e-05	0.0125	CbGdCrCtD
Lapatinib—Leukopenia—Epirubicin—prostate cancer	3.43e-05	0.00031	CcSEcCtD
Lapatinib—Back pain—Doxorubicin—prostate cancer	3.43e-05	0.000309	CcSEcCtD
Lapatinib—Constipation—Prednisone—prostate cancer	3.42e-05	0.000309	CcSEcCtD
Lapatinib—Hypersensitivity—Docetaxel—prostate cancer	3.42e-05	0.000308	CcSEcCtD
Lapatinib—Palpitations—Epirubicin—prostate cancer	3.39e-05	0.000306	CcSEcCtD
Lapatinib—Cough—Epirubicin—prostate cancer	3.35e-05	0.000302	CcSEcCtD
Lapatinib—Asthenia—Docetaxel—prostate cancer	3.33e-05	0.0003	CcSEcCtD
Lapatinib—Nausea—Etoposide—prostate cancer	3.32e-05	0.000299	CcSEcCtD
Lapatinib—Hypersensitivity—Capecitabine—prostate cancer	3.31e-05	0.000298	CcSEcCtD
Lapatinib—Pruritus—Docetaxel—prostate cancer	3.28e-05	0.000296	CcSEcCtD
Lapatinib—Anaemia—Doxorubicin—prostate cancer	3.28e-05	0.000296	CcSEcCtD
Lapatinib—Gastrointestinal pain—Prednisone—prostate cancer	3.27e-05	0.000295	CcSEcCtD
Lapatinib—Arthralgia—Epirubicin—prostate cancer	3.27e-05	0.000294	CcSEcCtD
Lapatinib—Myalgia—Epirubicin—prostate cancer	3.27e-05	0.000294	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	3.24e-05	0.000292	CcSEcCtD
Lapatinib—Asthenia—Capecitabine—prostate cancer	3.22e-05	0.000291	CcSEcCtD
Lapatinib—Pruritus—Capecitabine—prostate cancer	3.18e-05	0.000287	CcSEcCtD
Lapatinib—Leukopenia—Doxorubicin—prostate cancer	3.18e-05	0.000286	CcSEcCtD
Lapatinib—Diarrhoea—Docetaxel—prostate cancer	3.18e-05	0.000286	CcSEcCtD
Lapatinib—Abdominal pain—Prednisone—prostate cancer	3.16e-05	0.000285	CcSEcCtD
Lapatinib—Palpitations—Doxorubicin—prostate cancer	3.14e-05	0.000283	CcSEcCtD
Lapatinib—Anaphylactic shock—Epirubicin—prostate cancer	3.13e-05	0.000282	CcSEcCtD
Lapatinib—Infection—Epirubicin—prostate cancer	3.11e-05	0.00028	CcSEcCtD
Lapatinib—Cough—Doxorubicin—prostate cancer	3.1e-05	0.000279	CcSEcCtD
Lapatinib—Diarrhoea—Capecitabine—prostate cancer	3.07e-05	0.000277	CcSEcCtD
Lapatinib—Nervous system disorder—Epirubicin—prostate cancer	3.07e-05	0.000277	CcSEcCtD
Lapatinib—Skin disorder—Epirubicin—prostate cancer	3.04e-05	0.000274	CcSEcCtD
Lapatinib—Myalgia—Doxorubicin—prostate cancer	3.02e-05	0.000272	CcSEcCtD
Lapatinib—Arthralgia—Doxorubicin—prostate cancer	3.02e-05	0.000272	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	3e-05	0.000271	CcSEcCtD
Lapatinib—Anorexia—Epirubicin—prostate cancer	2.98e-05	0.000269	CcSEcCtD
Lapatinib—Vomiting—Docetaxel—prostate cancer	2.95e-05	0.000266	CcSEcCtD
Lapatinib—Hypersensitivity—Prednisone—prostate cancer	2.95e-05	0.000266	CcSEcCtD
Lapatinib—Rash—Docetaxel—prostate cancer	2.93e-05	0.000264	CcSEcCtD
Lapatinib—Dermatitis—Docetaxel—prostate cancer	2.92e-05	0.000264	CcSEcCtD
Lapatinib—Headache—Docetaxel—prostate cancer	2.91e-05	0.000262	CcSEcCtD
Lapatinib—Anaphylactic shock—Doxorubicin—prostate cancer	2.9e-05	0.000261	CcSEcCtD
Lapatinib—Infection—Doxorubicin—prostate cancer	2.88e-05	0.000259	CcSEcCtD
Lapatinib—Asthenia—Prednisone—prostate cancer	2.87e-05	0.000259	CcSEcCtD
Lapatinib—Vomiting—Capecitabine—prostate cancer	2.86e-05	0.000258	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Epirubicin—prostate cancer	2.85e-05	0.000257	CcSEcCtD
Lapatinib—Nervous system disorder—Doxorubicin—prostate cancer	2.84e-05	0.000256	CcSEcCtD
Lapatinib—Rash—Capecitabine—prostate cancer	2.83e-05	0.000255	CcSEcCtD
Lapatinib—Pruritus—Prednisone—prostate cancer	2.83e-05	0.000255	CcSEcCtD
Lapatinib—Insomnia—Epirubicin—prostate cancer	2.83e-05	0.000255	CcSEcCtD
Lapatinib—Dermatitis—Capecitabine—prostate cancer	2.83e-05	0.000255	CcSEcCtD
Lapatinib—Headache—Capecitabine—prostate cancer	2.82e-05	0.000254	CcSEcCtD
Lapatinib—Skin disorder—Doxorubicin—prostate cancer	2.81e-05	0.000254	CcSEcCtD
Lapatinib—Dyspnoea—Epirubicin—prostate cancer	2.79e-05	0.000252	CcSEcCtD
Lapatinib—Anorexia—Doxorubicin—prostate cancer	2.76e-05	0.000249	CcSEcCtD
Lapatinib—Nausea—Docetaxel—prostate cancer	2.76e-05	0.000249	CcSEcCtD
Lapatinib—Dyspepsia—Epirubicin—prostate cancer	2.76e-05	0.000248	CcSEcCtD
Lapatinib—Diarrhoea—Prednisone—prostate cancer	2.74e-05	0.000247	CcSEcCtD
Lapatinib—Decreased appetite—Epirubicin—prostate cancer	2.72e-05	0.000245	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Epirubicin—prostate cancer	2.7e-05	0.000244	CcSEcCtD
Lapatinib—Fatigue—Epirubicin—prostate cancer	2.7e-05	0.000243	CcSEcCtD
Lapatinib—Constipation—Epirubicin—prostate cancer	2.68e-05	0.000241	CcSEcCtD
Lapatinib—Nausea—Capecitabine—prostate cancer	2.67e-05	0.000241	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.64e-05	0.000238	CcSEcCtD
Lapatinib—Insomnia—Doxorubicin—prostate cancer	2.62e-05	0.000236	CcSEcCtD
Lapatinib—Dyspnoea—Doxorubicin—prostate cancer	2.58e-05	0.000233	CcSEcCtD
Lapatinib—Gastrointestinal pain—Epirubicin—prostate cancer	2.56e-05	0.000231	CcSEcCtD
Lapatinib—Dyspepsia—Doxorubicin—prostate cancer	2.55e-05	0.00023	CcSEcCtD
Lapatinib—Vomiting—Prednisone—prostate cancer	2.55e-05	0.000229	CcSEcCtD
Lapatinib—Rash—Prednisone—prostate cancer	2.52e-05	0.000227	CcSEcCtD
Lapatinib—Dermatitis—Prednisone—prostate cancer	2.52e-05	0.000227	CcSEcCtD
Lapatinib—Decreased appetite—Doxorubicin—prostate cancer	2.52e-05	0.000227	CcSEcCtD
Lapatinib—Headache—Prednisone—prostate cancer	2.51e-05	0.000226	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Doxorubicin—prostate cancer	2.5e-05	0.000225	CcSEcCtD
Lapatinib—Fatigue—Doxorubicin—prostate cancer	2.5e-05	0.000225	CcSEcCtD
Lapatinib—Constipation—Doxorubicin—prostate cancer	2.48e-05	0.000223	CcSEcCtD
Lapatinib—Abdominal pain—Epirubicin—prostate cancer	2.47e-05	0.000223	CcSEcCtD
Lapatinib—Nausea—Prednisone—prostate cancer	2.38e-05	0.000214	CcSEcCtD
Lapatinib—Gastrointestinal pain—Doxorubicin—prostate cancer	2.37e-05	0.000214	CcSEcCtD
Lapatinib—Hypersensitivity—Epirubicin—prostate cancer	2.31e-05	0.000208	CcSEcCtD
Lapatinib—Abdominal pain—Doxorubicin—prostate cancer	2.29e-05	0.000206	CcSEcCtD
Lapatinib—Asthenia—Epirubicin—prostate cancer	2.25e-05	0.000202	CcSEcCtD
Lapatinib—Pruritus—Epirubicin—prostate cancer	2.21e-05	0.0002	CcSEcCtD
Lapatinib—Diarrhoea—Epirubicin—prostate cancer	2.14e-05	0.000193	CcSEcCtD
Lapatinib—Hypersensitivity—Doxorubicin—prostate cancer	2.13e-05	0.000192	CcSEcCtD
Lapatinib—Asthenia—Doxorubicin—prostate cancer	2.08e-05	0.000187	CcSEcCtD
Lapatinib—Pruritus—Doxorubicin—prostate cancer	2.05e-05	0.000185	CcSEcCtD
Lapatinib—Vomiting—Epirubicin—prostate cancer	1.99e-05	0.000179	CcSEcCtD
Lapatinib—Diarrhoea—Doxorubicin—prostate cancer	1.98e-05	0.000179	CcSEcCtD
Lapatinib—Rash—Epirubicin—prostate cancer	1.97e-05	0.000178	CcSEcCtD
Lapatinib—Dermatitis—Epirubicin—prostate cancer	1.97e-05	0.000178	CcSEcCtD
Lapatinib—Headache—Epirubicin—prostate cancer	1.96e-05	0.000177	CcSEcCtD
Lapatinib—Nausea—Epirubicin—prostate cancer	1.86e-05	0.000168	CcSEcCtD
Lapatinib—Vomiting—Doxorubicin—prostate cancer	1.84e-05	0.000166	CcSEcCtD
Lapatinib—Rash—Doxorubicin—prostate cancer	1.83e-05	0.000165	CcSEcCtD
Lapatinib—Dermatitis—Doxorubicin—prostate cancer	1.82e-05	0.000164	CcSEcCtD
Lapatinib—Headache—Doxorubicin—prostate cancer	1.81e-05	0.000164	CcSEcCtD
Lapatinib—Nausea—Doxorubicin—prostate cancer	1.72e-05	0.000155	CcSEcCtD
Lapatinib—CYP3A4—Metabolism—GSTA4—prostate cancer	1.27e-06	1.1e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—TBXAS1—prostate cancer	1.27e-06	1.1e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—TYMS—prostate cancer	1.27e-06	1.1e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IL2—prostate cancer	1.26e-06	1.1e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—NQO1—prostate cancer	1.26e-06	1.09e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—KDR—prostate cancer	1.26e-06	1.09e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—PTGS2—prostate cancer	1.26e-06	1.09e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—GSTM1—prostate cancer	1.25e-06	1.09e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CYP2E1—prostate cancer	1.25e-06	1.08e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—TH—prostate cancer	1.24e-06	1.08e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.24e-06	1.07e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GSTA2—prostate cancer	1.23e-06	1.07e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—NQO1—prostate cancer	1.23e-06	1.07e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CYP3A4—prostate cancer	1.23e-06	1.07e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—RXRA—prostate cancer	1.23e-06	1.07e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—ESR1—prostate cancer	1.23e-06	1.07e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—LPL—prostate cancer	1.23e-06	1.07e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.22e-06	1.06e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—KRAS—prostate cancer	1.22e-06	1.06e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CTNNB1—prostate cancer	1.22e-06	1.06e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—SULT1A1—prostate cancer	1.22e-06	1.06e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ABCG5—prostate cancer	1.22e-06	1.06e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—TH—prostate cancer	1.21e-06	1.05e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CYP1B1—prostate cancer	1.21e-06	1.05e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—KRAS—prostate cancer	1.2e-06	1.04e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CYP3A4—prostate cancer	1.2e-06	1.04e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—BAD—prostate cancer	1.2e-06	1.04e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.2e-06	1.04e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—CDKN1B—prostate cancer	1.19e-06	1.03e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CDKN1A—prostate cancer	1.19e-06	1.03e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GSTA1—prostate cancer	1.19e-06	1.03e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—PTEN—prostate cancer	1.19e-06	1.03e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—CYP1A1—prostate cancer	1.19e-06	1.03e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—COMT—prostate cancer	1.18e-06	1.03e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CYP1B1—prostate cancer	1.18e-06	1.02e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—GSTP1—prostate cancer	1.18e-06	1.02e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—HSD3B2—prostate cancer	1.18e-06	1.02e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GSTO1—prostate cancer	1.18e-06	1.02e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—NAT2—prostate cancer	1.18e-06	1.02e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—AKT1—prostate cancer	1.18e-06	1.02e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—ERCC2—prostate cancer	1.18e-06	1.02e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—GGT1—prostate cancer	1.17e-06	1.02e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—APC—prostate cancer	1.16e-06	1.01e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PIK3CG—prostate cancer	1.16e-06	1.01e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—ITPR1—prostate cancer	1.16e-06	1.01e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—NCOA1—prostate cancer	1.15e-06	1e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IRS1—prostate cancer	1.15e-06	9.96e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—EGF—prostate cancer	1.15e-06	9.96e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—GGT1—prostate cancer	1.14e-06	9.92e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.14e-06	9.9e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CYP19A1—prostate cancer	1.14e-06	9.87e-06	CbGpPWpGaD
Lapatinib—EGFR—Immune System—EP300—prostate cancer	1.13e-06	9.84e-06	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—AKT1—prostate cancer	1.13e-06	9.8e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PLCB2—prostate cancer	1.13e-06	9.79e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP2C18—prostate cancer	1.13e-06	9.79e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—LRP2—prostate cancer	1.13e-06	9.79e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—CTNNB1—prostate cancer	1.13e-06	9.77e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—NCOA1—prostate cancer	1.13e-06	9.77e-06	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—PIK3CA—prostate cancer	1.12e-06	9.73e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—GSK3B—prostate cancer	1.11e-06	9.67e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CYP19A1—prostate cancer	1.11e-06	9.63e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—P4HB—prostate cancer	1.11e-06	9.6e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—MTHFR—prostate cancer	1.11e-06	9.59e-06	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—PIK3CA—prostate cancer	1.1e-06	9.59e-06	CbGpPWpGaD
Lapatinib—EGFR—Immune System—SRC—prostate cancer	1.1e-06	9.57e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—CDKN1A—prostate cancer	1.1e-06	9.55e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—INS—prostate cancer	1.1e-06	9.53e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—PTEN—prostate cancer	1.1e-06	9.52e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—RXRA—prostate cancer	1.1e-06	9.52e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—TYMS—prostate cancer	1.1e-06	9.51e-06	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—TP53—prostate cancer	1.09e-06	9.42e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PPARA—prostate cancer	1.08e-06	9.41e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—GSTM1—prostate cancer	1.08e-06	9.4e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—SLC22A1—prostate cancer	1.08e-06	9.34e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CREBBP—prostate cancer	1.08e-06	9.34e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—RXRA—prostate cancer	1.07e-06	9.29e-06	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—TP53—prostate cancer	1.07e-06	9.27e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.07e-06	9.26e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—LPL—prostate cancer	1.06e-06	9.23e-06	CbGpPWpGaD
Lapatinib—EGFR—Immune System—STAT3—prostate cancer	1.06e-06	9.23e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IGF1—prostate cancer	1.06e-06	9.22e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—COMT—prostate cancer	1.06e-06	9.17e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—GSTP1—prostate cancer	1.05e-06	9.13e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—SULT2A1—prostate cancer	1.05e-06	9.1e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—EP300—prostate cancer	1.05e-06	9.08e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—ITPR1—prostate cancer	1.04e-06	8.98e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—MED12—prostate cancer	1.03e-06	8.96e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—COMT—prostate cancer	1.03e-06	8.95e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MAP2K1—prostate cancer	1.03e-06	8.91e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—GSTP1—prostate cancer	1.03e-06	8.91e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CYP1A1—prostate cancer	1.03e-06	8.91e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GNG5—prostate cancer	1.02e-06	8.89e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PIK3CD—prostate cancer	1.02e-06	8.85e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—CAV1—prostate cancer	1.02e-06	8.85e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—ERCC2—prostate cancer	1.02e-06	8.84e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.02e-06	8.83e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—SRC—prostate cancer	1.02e-06	8.83e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—ITPR1—prostate cancer	1.01e-06	8.77e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—SERPINE1—prostate cancer	1.01e-06	8.76e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—KRAS—prostate cancer	9.99e-07	8.67e-06	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—IL6—prostate cancer	9.93e-07	8.62e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—NCOA3—prostate cancer	9.87e-07	8.56e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—STAT3—prostate cancer	9.82e-07	8.52e-06	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—IL6—prostate cancer	9.78e-07	8.49e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—TYMS—prostate cancer	9.78e-07	8.49e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—FGF2—prostate cancer	9.77e-07	8.48e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—GSTM1—prostate cancer	9.67e-07	8.39e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NOS3—prostate cancer	9.64e-07	8.36e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—MTHFR—prostate cancer	9.57e-07	8.31e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—TYMS—prostate cancer	9.55e-07	8.28e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—LPL—prostate cancer	9.49e-07	8.23e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—GSTM1—prostate cancer	9.44e-07	8.19e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—HPGDS—prostate cancer	9.41e-07	8.17e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PPARA—prostate cancer	9.39e-07	8.15e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—JAK2—prostate cancer	9.37e-07	8.13e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP2C19—prostate cancer	9.35e-07	8.11e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PIK3CG—prostate cancer	9.29e-07	8.06e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—LPL—prostate cancer	9.26e-07	8.04e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—PIK3CA—prostate cancer	9.18e-07	7.96e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CYP1A1—prostate cancer	9.17e-07	7.95e-06	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—AKT1—prostate cancer	9.16e-07	7.95e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MDM2—prostate cancer	9.14e-07	7.93e-06	CbGpPWpGaD
Lapatinib—EGFR—Immune System—KRAS—prostate cancer	9.13e-07	7.92e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GSTT1—prostate cancer	9.13e-07	7.92e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ACHE—prostate cancer	9.13e-07	7.92e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—MYC—prostate cancer	9.12e-07	7.91e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—TGFB1—prostate cancer	9.1e-07	7.9e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—ERCC2—prostate cancer	9.09e-07	7.89e-06	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—AKT1—prostate cancer	9.03e-07	7.83e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP2A6—prostate cancer	9.02e-07	7.83e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—ERBB2—prostate cancer	9.01e-07	7.82e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CYP1A1—prostate cancer	8.95e-07	7.76e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PIK3CB—prostate cancer	8.9e-07	7.72e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—ERCC2—prostate cancer	8.87e-07	7.7e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CAV1—prostate cancer	8.83e-07	7.66e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—INS—prostate cancer	8.79e-07	7.63e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—AKR1C3—prostate cancer	8.78e-07	7.62e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PRKACB—prostate cancer	8.73e-07	7.58e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP17A1—prostate cancer	8.64e-07	7.5e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—CREBBP—prostate cancer	8.61e-07	7.47e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CXCL8—prostate cancer	8.55e-07	7.42e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—MTHFR—prostate cancer	8.54e-07	7.41e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	8.44e-07	7.32e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—KRAS—prostate cancer	8.43e-07	7.31e-06	CbGpPWpGaD
Lapatinib—EGFR—Immune System—PIK3CA—prostate cancer	8.39e-07	7.28e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PPARA—prostate cancer	8.38e-07	7.27e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CDKN1B—prostate cancer	8.35e-07	7.24e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—MTHFR—prostate cancer	8.34e-07	7.24e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—NCOA2—prostate cancer	8.23e-07	7.14e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PPARA—prostate cancer	8.18e-07	7.1e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CASP3—prostate cancer	8.18e-07	7.1e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IL2—prostate cancer	8.17e-07	7.09e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PIK3CD—prostate cancer	8.16e-07	7.08e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—IL6—prostate cancer	8.13e-07	7.05e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PIK3CG—prostate cancer	8.04e-07	6.98e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CCND1—prostate cancer	7.96e-07	6.91e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CTNNB1—prostate cancer	7.89e-07	6.84e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CAV1—prostate cancer	7.88e-07	6.84e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—SLC5A5—prostate cancer	7.85e-07	6.82e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—PIK3CA—prostate cancer	7.74e-07	6.72e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MMP9—prostate cancer	7.73e-07	6.71e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—NOS3—prostate cancer	7.71e-07	6.69e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CDKN1A—prostate cancer	7.7e-07	6.68e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CAV1—prostate cancer	7.69e-07	6.68e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PTEN—prostate cancer	7.69e-07	6.67e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP2E1—prostate cancer	7.67e-07	6.66e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—INS—prostate cancer	7.61e-07	6.61e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—NQO1—prostate cancer	7.59e-07	6.58e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	7.53e-07	6.53e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—AKT1—prostate cancer	7.5e-07	6.51e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—TH—prostate cancer	7.48e-07	6.49e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CREBBP—prostate cancer	7.46e-07	6.47e-06	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IL6—prostate cancer	7.43e-07	6.44e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—EP300—prostate cancer	7.33e-07	6.36e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP1B1—prostate cancer	7.27e-07	6.31e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PIK3CG—prostate cancer	7.18e-07	6.23e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—SRC—prostate cancer	7.13e-07	6.18e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PIK3CB—prostate cancer	7.12e-07	6.17e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PIK3CD—prostate cancer	7.07e-07	6.14e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PTGS2—prostate cancer	7.05e-07	6.12e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GGT1—prostate cancer	7.04e-07	6.11e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PIK3CG—prostate cancer	7.01e-07	6.08e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—VEGFA—prostate cancer	6.94e-07	6.02e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—NCOA1—prostate cancer	6.94e-07	6.02e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—STAT3—prostate cancer	6.87e-07	5.96e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—IL6—prostate cancer	6.86e-07	5.95e-06	CbGpPWpGaD
Lapatinib—EGFR—Immune System—AKT1—prostate cancer	6.85e-07	5.94e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP19A1—prostate cancer	6.84e-07	5.93e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—INS—prostate cancer	6.8e-07	5.9e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—NOS3—prostate cancer	6.68e-07	5.79e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CREBBP—prostate cancer	6.66e-07	5.78e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—INS—prostate cancer	6.63e-07	5.76e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—RXRA—prostate cancer	6.6e-07	5.73e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CREBBP—prostate cancer	6.5e-07	5.64e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MYC—prostate cancer	6.39e-07	5.54e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TGFB1—prostate cancer	6.37e-07	5.53e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—COMT—prostate cancer	6.36e-07	5.52e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GSTP1—prostate cancer	6.33e-07	5.49e-06	CbGpPWpGaD
Lapatinib—EGFR—Disease—AKT1—prostate cancer	6.33e-07	5.49e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PIK3CD—prostate cancer	6.31e-07	5.48e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ITPR1—prostate cancer	6.23e-07	5.4e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PIK3CB—prostate cancer	6.16e-07	5.35e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PIK3CD—prostate cancer	6.16e-07	5.34e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PTEN—prostate cancer	6.15e-07	5.34e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PTGS2—prostate cancer	6.11e-07	5.3e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—NOS3—prostate cancer	5.96e-07	5.17e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—KRAS—prostate cancer	5.9e-07	5.12e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—TYMS—prostate cancer	5.88e-07	5.1e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—EP300—prostate cancer	5.86e-07	5.09e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—NOS3—prostate cancer	5.82e-07	5.05e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GSTM1—prostate cancer	5.81e-07	5.04e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—LPL—prostate cancer	5.71e-07	4.95e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP1A1—prostate cancer	5.51e-07	4.78e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PIK3CB—prostate cancer	5.5e-07	4.77e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ERCC2—prostate cancer	5.47e-07	4.74e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PTGS2—prostate cancer	5.45e-07	4.73e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PIK3CA—prostate cancer	5.42e-07	4.7e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PIK3CB—prostate cancer	5.37e-07	4.66e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PTEN—prostate cancer	5.33e-07	4.62e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PTGS2—prostate cancer	5.32e-07	4.62e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TP53—prostate cancer	5.25e-07	4.55e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—MTHFR—prostate cancer	5.14e-07	4.46e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—EP300—prostate cancer	5.08e-07	4.41e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PPARA—prostate cancer	5.04e-07	4.37e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IL6—prostate cancer	4.8e-07	4.17e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PTEN—prostate cancer	4.75e-07	4.12e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CAV1—prostate cancer	4.74e-07	4.11e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PTEN—prostate cancer	4.64e-07	4.03e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—EP300—prostate cancer	4.53e-07	3.93e-06	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—AKT1—prostate cancer	4.43e-07	3.84e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—EP300—prostate cancer	4.42e-07	3.84e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PIK3CA—prostate cancer	4.34e-07	3.76e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PIK3CG—prostate cancer	4.32e-07	3.75e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—INS—prostate cancer	4.09e-07	3.55e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CREBBP—prostate cancer	4e-07	3.47e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PIK3CD—prostate cancer	3.8e-07	3.29e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PIK3CA—prostate cancer	3.76e-07	3.26e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—NOS3—prostate cancer	3.58e-07	3.11e-06	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—AKT1—prostate cancer	3.54e-07	3.07e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PIK3CA—prostate cancer	3.35e-07	2.91e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PIK3CB—prostate cancer	3.31e-07	2.87e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PTGS2—prostate cancer	3.28e-07	2.84e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PIK3CA—prostate cancer	3.27e-07	2.84e-06	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—AKT1—prostate cancer	3.07e-07	2.66e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PTEN—prostate cancer	2.86e-07	2.48e-06	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—AKT1—prostate cancer	2.74e-07	2.38e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—EP300—prostate cancer	2.73e-07	2.37e-06	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—AKT1—prostate cancer	2.67e-07	2.32e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PIK3CA—prostate cancer	2.02e-07	1.75e-06	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—AKT1—prostate cancer	1.65e-07	1.43e-06	CbGpPWpGaD
